MARYLAND PAIN ATLAS · VERIFIED BASELINE

Maryland must identify who owns two conditions of authorization.

Current Maryland HealthChoice materials require random toxicology testing and a signed opioid treatment agreement for some ongoing outpatient opioid authorization. Maryland also hosts an older universal form containing the same conditions. The first task is to identify the current authority, then remove the conditions wherever they operate categorically.

See the exact request
Use the national method
All 50 states

Status: Verified baseline. Official state sources checked September 8, 2026. Current plan findings retain their recorded August 2026 verification dates. No agency answer or policy result is claimed on this page.

This is public policy education and source mapping, not medical or legal advice.

EXECUTIVE FINDING

The requirements are visible. Their present owner is not.

Priority Partners, MedStar Family Choice, and CareFirst Community Health Plan Maryland materials reviewed for this Atlas each reproduced random drug screening and a signed pain management or opioid treatment agreement as authorization conditions. Priority Partners also stated that its opioid policies applied to both the plan and Maryland Medicaid fee for service.

Maryland continues to host a Universal Opioid Prior Authorization Form marked Updated October 2017. It contains the same two attestations and identifies Medicaid fee for service and listed managed care organizations. Its age creates a verification duty. The current record does not establish that this old form remains the operative fee for service instrument.

One state action sentence: Maryland should identify the current fee for service and HealthChoice authority for random toxicology testing and a signed opioid treatment agreement, then remove either measure wherever it operates as a categorical coverage condition rather than an individualized clinical decision.

CLASSIFICATION METHOD

Separate the policy from the people administering it.

  • Decision authority: an office that can withdraw, amend, interpret, or direct revision of the challenged condition.
  • Implementation authority: an office that controls whether reform reaches pharmacy claims, managed care, or professional systems.
  • Review authority: an institution that can approve, reject, recommend, or oversee the requested action.
  • Documented ally: a person or institution with a current attributable action supporting the specific reform or its substantive equivalent.
  • Unclassified: relevant authority without a verified present position on this request.

Silence is not opposition. Inherited administration is not proof of personal support. No Maryland official is classified on this baseline page.

CONTROLLING AUTHORITIES

Who controls what in Maryland

Maryland Department of Health

Holds department level authority over Medicaid administration and can identify the source and status of statewide policy.

Maryland Medicaid

Controls fee for service pharmacy policy and oversees the HealthChoice managed care structure.

Office of Pharmacy Services

Administers pharmacy criteria, forms, claims operations, and provider guidance within Maryland Medicaid.

Drug Use Review Board

Reviews drug utilization and can make recorded recommendations. Its advisory role should not be confused with final decision authority.

HealthChoice plans

Publish and implement plan criteria. Each plan should identify which condition comes from Maryland and which is independently chosen.

Board of Physicians

Controls physician professional standards. It does not own a Medicaid coverage condition merely because the condition affects physicians.

Board of Pharmacy

Regulates pharmacy practice and should identify any separate dispensing rule relevant to the challenged conditions.

Maryland General Assembly

Provides oversight and a legislative remedy if administrative authority is unclear or insufficient.

CONTROLLING RECORD

Do not confuse statute, payer policy, and clinical guidance.

  • Health Occupations section 1 223: requires the lowest effective opioid dose based on clinical judgment and limits quantity to the expected duration of sufficiently severe pain, with chronic pain written as an exception to the quantity provision.
  • No statutory 90 MME ceiling: the General Assembly did not place a universal adult chronic pain dosage ceiling in section 1 223.
  • Independent PDMP requirement: Maryland separately requires prescription monitoring in defined circumstances. That protection is outside this request.
  • State hosted 2017 form: the Universal Opioid Prior Authorization Form contains random urine screening and signed agreement attestations, but its present fee for service status must be confirmed.
  • Current plan evidence: the same two conditions appeared in current Priority Partners, MedStar Family Choice, and CareFirst Community Health Plan Maryland materials reviewed for this Atlas.
  • Federal safety edit requirement: federal Medicaid law requires an opioid safety edit structure. That does not by itself establish a universal random testing or signed agreement condition.

The record establishes authorization requirements. It does not yet establish how often either condition causes a denial, delayed fill, abandoned request, or loss of treatment. That consequence requires aggregate outcome data or a documented Maryland case.

THE EXACT REQUEST

Identify the authority. Remove the two categorical conditions.

I am asking the Maryland Department of Health and Maryland Medicaid to identify the current fee for service and HealthChoice authority, if any, requiring random toxicology testing and execution of a pain management or opioid treatment agreement for ongoing outpatient opioid prior authorization. Wherever either measure operates as a categorical Maryland Medicaid coverage condition, remove it while preserving prescription monitoring, individualized prior authorization, lawful opioid safety edits, fraud and diversion review, medical necessity review, and ordinary professional standards.

If the conditions are entirely plan created, Maryland should state that conclusion in writing so each plan can be addressed under the correct authority.

READY TO ADAPT LANGUAGE

The initial Maryland inquiry

Please identify whether the Universal Opioid Prior Authorization Form marked Updated October 2017 remains operative for Maryland Medicaid fee for service. If it does not, please identify the current form, policy, transmittal, claims criterion, or other instrument that replaced it.

Please identify the present authority for random toxicology testing and a signed pain management or opioid treatment agreement in fee for service and HealthChoice authorization. State whether each condition is imposed by Maryland Medicaid, the Drug Use Review Board, the managed care contract, an individual plan, or another source.

An otherwise approvable opioid authorization request should not be denied, returned as incomplete, or refused processing solely because random testing has not been imposed or a separate opioid treatment agreement has not been executed. Testing and written planning may remain available when clinically appropriate.

Use the verified department channel and current recipient. One genuine request with a preserved record is stronger than identical mass submissions.

ACTION CALENDAR

A disciplined 60 day Maryland sequence

  1. Days 1 through 7: preserve the current state form, current fee for service criteria, plan criteria, managed care contract, and official contact channels.
  2. Days 8 through 14: send the administrative inquiry and a focused Maryland Public Information Act request at the same time.
  3. Days 15 through 30: build a current HealthChoice plan matrix identifying testing, agreement, dosage, naloxone, exemption, duration, and appeal provisions.
  4. Days 31 through 45: classify each condition by owner and obtain existing aggregate records on incomplete, denied, or abandoned authorization requests.
  5. Days 46 through 60: request the narrow correction from the responsible office and publish only verified responses and measurable results.

MEASURABLE OBJECTIVES

What counts as Maryland progress

  • A written answer on whether the 2017 form remains operative for fee for service.
  • A named owner and controlling source for each challenged condition.
  • A completed matrix covering every current HealthChoice plan.
  • Existing outcome data or a documented statement that Maryland does not maintain it.
  • Removal of categorical random testing and signed agreement conditions from state policy.
  • A written implementation direction distinguishing state requirements from independent plan choices.
  • Updated materials that do not attribute a state selected threshold to superseded federal guidance.

A form, meeting, or assurance is activity. It becomes progress only when a dated public record supports the claim.

FEDERAL CONNECTION

Federal safety edits do not answer the Maryland ownership question.

Maryland must maintain a lawful opioid safety edit structure for Medicaid. That does not automatically require every affected patient to undergo random testing or sign a separate opioid agreement. If Maryland attributes either condition to federal law or enforcement, ask for the controlling federal provision.

The federal inquiry should remain separate from Maryland Medicaid, managed care, professional regulation, and clinical office policy. Medical access remains local even when federal coordination matters.

Open the DEA Division Atlas

ESCALATION AND COOPERATION

Use the narrowest authority capable of changing the condition.

  1. Request verification and voluntary correction from Maryland Medicaid.
  2. Use the Public Information Act to identify the controlling instrument and available outcome records.
  3. Present the record to the Drug Use Review Board when its recommendation is relevant.
  4. Use the appropriate administrative or regulatory process if a binding state rule must change.
  5. Address an individual plan when Maryland establishes that the condition is independently created.
  6. Seek legislative oversight only when administrative authority is absent, disputed, or refused.

Cooperation path: pause escalation when Maryland identifies the current authority, removes a categorical condition, corrects obsolete materials, or creates a transparent individualized review route. The objective is clear ownership and lawful access, not institutional humiliation.

OFFICIAL SOURCE RECORD

Maryland primary and controlling sources

Historical context: Seeds of Vice calculated that Maryland retail opioid dispensing declined 54.4 percent from 2012 through 2023, 45.3 percent from 2006 through 2023, and 22.2 percent from 2019 through 2023 using archived annual state table endpoints. Those calculations do not prove criminality, medical appropriateness, patient effect, or DEA causation.

Evidentiary limit: this page does not claim a universal Maryland adult chronic pain dosage or duration cap. It does not import a District of Columbia trigger or a Virginia acute pain rule into Maryland. It distinguishes an authorization condition from proof that the condition caused a specific denial.

Source note: forms, contracts, criteria, personnel, and plan requirements can change. Verify every current instrument before contact or filing.

Correction history: August 7, 2026, legal review narrowed the statutory interpretation, preserved the 2017 form as historical and currently hosted evidence, added current plan evidence, added the authority inquiry, and prohibited unsupported denial claims. September 8, 2026, the page was reorganized into the Oklahoma atlas architecture and duplicated legacy material was removed without changing the central request.

Maryland’s first proof is ownership.

The state does not need to defend an unnamed policy. It needs to identify who requires each condition, what instrument creates it, and why an otherwise approvable request should fail solely because random testing or a separate opioid agreement is absent.

Build one request
See Proof of Progress